Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.00    3.20 (2.09%)
Bid:
155.80
Ask:
156.20
Spread: 0.40 (0.257%)
Market Cap: £892.81m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Statement

24 Jun 2015 07:00

RNS Number : 0217R
Elementis PLC
24 June 2015
 



Elementis plc - Trading update

 

Elementis plc (ELM.L, the "Company" or the "Group"), the Global Specialty Chemicals Company, today issues a trading update ahead of its interim results for the half year ending 30 June 2015, which will be announced on 28 July 2015.

 

Specialty Products continues to make solid progress in terms of leveraging its strong market positions and geographic diversity, and developing new and innovative products to solve our customers' formulary challenges. Market share and contribution margins have remained stable and trading in the first half of the year is anticipated to be in line with management's expectations in most of our key markets. However, temporary market dynamics experienced in the second quarter of the year will most likely negatively influence our full year result.

 

· As recent commentary from the oil sector confirms, there has been a further significant reduction in oil projects in North America and therefore drilling activity has been further curtailed. As a result, we now expect our sales of additives for the first half and the year as a whole to the oilfield drilling market to be at least 30 per cent lower than the previous year, driven by lower volumes.

 

· In coatings additives, the Group continues to make good progress in North America, where the uptake of the new additives line for decorative coatings from our New Martinsville facility is continuing to gain traction with customers. Sales to Latin America have also been robust, based on synergy projects from the previously acquired Watercryl business. In Europe, where underlying economic activity still remains subdued, Group sales for the first half of the year, on a constant currency basis, are expected to be ahead of the same period last year. However, additives sales in China have experienced a reduction in demand during the second quarter of the year and, while the Group still expects sales to be ahead of prior year for the year as a whole, Asia Pacific sales in the first half will be similar to the same period last year. Consequently, overall sales of coatings additives for the first six months of the year, on a constant currency basis, are expected to be at a similar level to the same period last year.

 

· In personal care, the business continues to expand through new product sales and investments into new geographies. However, sales in Latin America have been impacted by significant local currency weakness. This has resulted in the business opting to cease supplying to a number of applications where returns have fallen below an acceptable threshold. The business is taking decisive action to address this competitive dynamic and market share gains from new product introductions have helped to offset the Latin America shortfall. Therefore, sales for the first half will be similar to the strong 2014 first half results. Additionally, positive trends in other markets and geographies mean that full year sales, on a constant currency basis, are expected to be ahead of the previous year.

 

In Chromium, the market trends outlined in the Group's Interim Management Statement in April have continued through the balance of the first half of the year. As such, management expects the operating profit for the full year to be in line with the stated strategy for the business of "stable earnings and cash flow" and the first half result to be similar to the same period last year.

 

The Group's balance sheet remains in a strong position and is expected to show a net cash position at the end of the current year. While the Group remains confident in continuing to make progress in the medium term, the cumulative impact of short term issues arising during the second quarter, as described above, is that earnings per share for the full year are anticipated to be below the current range of market expectations.

 

 

ENDS

 

Enquiries:

Elementis + 44 (0) 207 408 9300

David Dutro, Chief Executive

Brian Taylorson, Finance Director

  

FTI Consulting

 

 

+ 44 (0) 203 727 1000

Deborah Scott

Matthew Cole

  

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFJMPTMBATBIA
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.